fbpx

Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities. Get Free Email Updates

Stay Competitive With Stock Market Updates!

Get Free Updates

INMB

INmune Bio Inc.

  ( )

Page Views : 5977

vista's key points

  • An exciting clinical stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer.
  • INKmune, the company’s lead product, primes patient’s NK cells (natural killer cells) to kill cancer.
  • INmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse.
  • By controlling residual disease, INmune believes that patients may live longer.
  • Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells’ ability to eliminate residual disease.

vista's key points

  • An exciting clinical stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer.
  • INKmune, the company’s lead product, primes patient’s NK cells (natural killer cells) to kill cancer.
  • INmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse.
  • By controlling residual disease, INmune believes that patients may live longer.
  • Using a novel mechanism of action and a precision medicine approach, INKmune therapy should enhance NK cells’ ability to eliminate residual disease.

company profile

 

vista's view

INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The DN-TNF product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction...

Read More

vp watchlist

The VP Watchlist contains current coverage companies that deserve consideration for short term and long term portfolio additions.

Stay Informed. Stay Competitive with FREE Insights on the Stock Market, Dow 30 & Emerging Opportunities.

Get Free Email Updates